Top

Italian Journal of Pediatrics

Published in:

Open Access 01-12-2019 | Imipenem | Research

Isolation and identification of Pandoraea spp. From bronchoalveolar lavage of cystic fibrosis patients in Iran

Authors: Mohammad Tabatabaei, Mahdi Dastbarsar, Mohammad Ashkan Moslehi

Published in: Italian Journal of Pediatrics | Issue 1/2019

Abstract

Background

Pandoraea species are gram negative, motile, non-spore forming, rod shaped and oxidase positive, obligate aerobes bacteria, and have one polar flagellum. Most of Pandoraea species are associated with lung infections in cystic fibrosis patients. Cystic fibrosis is the most prevalent autosomal recessive hereditary disease in the world that affects various organs of the body. The main important cause of death in these patients is lung involvement. This study was conducted to isolate and identify Pandoraea bacterium from bronchoalveolar lavage and sputum samples of cystic fibrosis patients in Shiraz, Iran.

Methods

In this research 31 samples of bronchoalveolar lavage and sputum were examined by culture and PCR method. Then confirmed isolates were evaluated for susceptibility to different antibiotics and ability to produce biofilm.

Results

The results of this study after cultivation, purification and DNA extraction led to the isolation of 4 Pandoraea bacterium by PCR using specific primers. Antibiotic susceptibility test were indicated all isolates were resistant to gentamicin, amikacin and imipenem and susceptible to ciprofloxacin, trimethoprim-sulfumethoxazole, piperacillin and tetracycline. Ability to create biofilm was indicated by some of Pandoraea isolates. According to findings of this study, ability to synthesis biofilm by Pandoraea isolates and resistance to some antibiotics are very important.

Conclusions

Our study notes the role of P. pnomenusa as an emerging pathogen that can cause chronic lung colonization in CF patients. Identification tools need to be accurate and must be based on molecular techniques. Also our findings should raise awareness about antibiotic resistance in cystic fibrosis patients in Iran and ability of including bacterial agents to produce biofilm is an alarm for public health. Thus clinicians should exercise caution about finding of clinical relevance of this pathogen to the infection and prescribing antibiotics, especially in cases of children infections.

Coenye T, Falsen E, Hoste B, Ohle’n M, Goris J, JRW G, et al. Description of Pandoraea gen. Nov. with Pandoraea apista sp. nov., Pandoraea pulmonicola sp. nov., Pandoraea pnomenusa sp. nov., Pandoraea sputorum sp. nov. and Pandoraea norimbergensis comb. nov. Int J Syst Evol Microbiol. 2000;50:887–99.CrossRef

Daneshvar MI, Hollis DG, Steigerwalt AG, Whitney AM, Spangler L, Douglas MP, et al. Assignment of CDC weak oxidizer group 2 (WO-2) to the genus Pandoraea and characterization of three new Pandoraea genomospecies. J Clin Microbiol. 2001;39:1819–26.PubMedPubMedCentralCrossRef

See-Too WS, Ambrose M, Malley R, Ee R, Mulcahy E, Manche E, et al. Pandoraea fibrosis sp. nov., a novel Pandoraea species isolated from clinical respiratory samples. Int J Syst Evol Microbiol. 2019;69(3):645–51. https://doi.org/10.1099/ijsem.0.003147.PubMedCrossRef

Degand N, Lotte R, Le Butor CD, Segonds C, Thouverez M, Ferroni A, et al. Epidemic spread of Pandoraea pulmonicolain a cystic fibrosis center. BMC Infect Dis. 2015;15:583. https://doi.org/10.1186/s12879-015-1327-8.PubMedPubMedCentralCrossRef

Jeong SE, Lee HJ, Jia B, Jeon CO. Pandoraea terrae sp. nov., isolated from forest soil, and emended description of the genus Pandoraea Coenye et al. 2000. Int J Syst Evol Microbiol. 2016;66(9):3524–30. https://doi.org/10.1099/ijsem.0.001229.PubMedCrossRef

Henry DA, Mahenthiralingam E, Vandamme P, Coenye T, Speert DP. Phenotypic methods for determining genomovar status of the Burkholderia cepacia complex. J Clin Microbiol. 2001;39:1073–8.PubMedPubMedCentralCrossRef

Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066–73.PubMedCrossRef

Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998;95:1005–15.PubMedCrossRef

Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J RespirCrit Care Med. 2003;168:918–51.CrossRef

10.

Martina PF, Martínez M, Frada G, Alvarez F, Leguizamón L, Prieto C, et al. First time identification of Pandoraea sputorum from a patient with cystic fibrosis in Argentina: a case report. BMC Pulmon Medici. 2017;17:33. https://doi.org/10.1186/s12890-017-0373-y.

11.

LiPuma JJ. Burkholderia and emerging pathogens in cystic fibrosis. Semin Respir Crit Care Med. 2003;24:681–92.PubMedCrossRef

12.

Pimentel JD, MacLeod C. Misidentification of Pandoraea sputorum isolated from sputum of a patient with cystic fibrosis and review of Pandoraea species infections in transplant patients. J Clin Microbiol. 2008;46:3165–8.PubMedPubMedCentralCrossRef

13.

Atkinson RM, Lipuma JJ, Rosenbluth DB, Dunne WM Jr. Chronic colonization with Pandoraea apista in cystic fibrosis patients determined by repetitive-element-sequence PCR. J Clin Microbiol. 2006;44:833–6.PubMedPubMedCentralCrossRef

14.

Stryjewski ME, LiPuma JJ, Messier RH Jr, Reller LB, Alexander BD. Sepsis, multiple organ failure, and death due to Pandoraea pnomenusa infection after lung transplantation. J Clin Microbiol. 2003;41:2255–7.PubMedPubMedCentralCrossRef

15.

Schneider I, Queenan AM, Bauernfeind A. Novel carbapenem-hydrolyzing oxacillinase OXA-62 from Pandoraea pnomenusa. Antimicrob Agents Chemother. 2006;50:1330–5.PubMedPubMedCentralCrossRef

16.

Burns JL, Jonas M, Chi EY, Clark DK, Berger A, Griffith A. Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia. Infect Immun. 1996;64:4054–9.PubMedPubMedCentral

17.

Cieri MV, Mayer-Hamblett N, Griffith A, Burns JL. Correlation between an in vitro invasion assay and a murine model of Burkholderia cepacia lung infection. Infect Immun. 2002;70:108–6.CrossRef

18.

Duff C, Murphy PG, Callaghan M, McClean S. Differences in invasion and translocation of Burkholderia cepacia complex species in polarized lung epithelial cells in vitro. Microb Pathog. 2006;4:183–92.CrossRef

19.

Caraher E, Collins J, Herbert G, Philip G, Murphy PG, Gallagher CG, Crowe MJ, et al. Evaluation of in vitro virulence characteristics of the genus Pandoraea in lung epithelial cells. J Med Microbiol. 2008;57(Pt 1):15–20.PubMedCrossRef

20.

Green H, Jones AM. Emerging gram-negative bacteria: pathogenic or innocent bystanders. Curr Opin Pulm Med, 2018; 24:000–000. https://doi.org/10.1097/MCP.0000000000000517.

21.

Caraher E, Duff C, Mullen T, Mc Keon S, Murphy P, Callaghan M, McClean S. Invasion and biofilm formation of Burkholderia dolosa is comparable with Burkholderia cenocepacia and Burkholderia multivorans. J Cyst Fibros. 2007;6:49–56.PubMedCrossRef

22.

Chernish RN, Aaron SD. Approach to resistant gram negative bacterial pulmonary infections in patients with cystic fibrosis. Curr Opin Pulm Med. 2003;9:509–15.PubMedCrossRef

23.

Hoiby N, Krogh Johansen H, Moser C, Song Z, Ciofu O, Kharazmi A. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect. 2001;3:23–35.PubMedCrossRef

24.

Yu H, Head NE. Persistent infections and immunity in cystic fibrosis. Front Biosci. 2002;7:d442–57.PubMedCrossRef

25.

Moore JE, Coenye T, Vandamme P, Elborn JS. First report of Pandoraea norimbergensis isolated from food-potential clinical significance. Food Microbiol. 2001;18:113–4.CrossRef

26.

Coenye T, Liu L, Vandamme P, LiPuma JJ. Identification of Pandoraea species by 16S ribosomal DNA-based PCR assays. J Clin Microbiol. 2001;39:4452–5.PubMedPubMedCentralCrossRef

27.

CLSI. M100-S25. Performance standards for antimicrobial susceptibility testing; Twenty-fifth informational supplement; 2015.

28.

Merritt J, Kadour D, O'Toole G. Growing and analyzing static biofilms, Curr Protoc Microbiol. 01 2005; Unite1B.1.

29.

Wakimoto N, Nishi J, Sheikh J, Nataro J, Sarantuya J, Iwashita M, Manago K, Tokuda K, Yoshinag M, Kawano Y. Quantitative biofilm assay using a microtiter plate to screen for enteroaggregative Escherichia coli. Am J Tro Med Hyg. 2004;71:687e690.

30.

Edward T. Essential Medical Genetics, 2011. John Wiley & Sons. p. 312. ISBN 1-118-29370-3. Archived from the original on 2016-04-17.

31.

The canadian facts & figures on cystic fibrosis. Archived from the original on 2013-06-16.

32.

"Genetic Carrier Testing". Cystic Fibrosis Foundation. 2007. Archived from the original on 2010-03-23.

33.

Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation consensus panel. J Pediatr. 1998;132(4):58995. https://doi.org/10.1016/S0022-3476(98)70344-0.PMID9580754.CrossRef

34.

Hamosh A, FitzSimmons SC, Macek M, Knowles MR, Rosenstein BJ, Cutting GR. Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr. 1998;132(2):255–9. https://doi.org/10.1016/S0022-3476(98)70441-X.PMID9506637.PubMedCrossRef

35.

Farrell P, Joffe S, Foley L, Canny GJ, Mayne P, Rosenberg M. Diagnosis of cystic fibrosis in the Republic of Ireland: epidemiology and costs. Ir Med J 2007;100 (8): 557–560. PMID 17955689. Archived from the original on 2013-12-03.

36.

Karatan E, Watnick P. Signals, regulatory networks, and materials that build and break bacterial biofilms. Microbiol Mol Biol Rev. 2009;73:310–47.PubMedPubMedCentralCrossRef

37.

Panickar J, David T. Prevalence of emerging pathogens in a large paediatric CF centre. J Cyst Fibros. 2015;14:S68.CrossRef

38.

Ambrose M, Malley RC, Warren SJC, Beggs SA, Swallow OFE, McEwan B, et al. Pandoraea pnomenusa isolated from an Australian patient with cystic fibrosis. Front Microbiol. 2016;7:692. https://doi.org/10.3389/fmicb.2016.00692.PubMedPubMedCentralCrossRef

39.

Mahenthiralingam E. Emerging cystic fibrosis pathogens and the microbiome. Paediatr Respir Rev. 2014;15:13–5. https://doi.org/10.1016/j.prrv.2014.04.006.PubMedCrossRef

40.

Fernández-Olmos A, Morosini MI, Lamas A, García-Castillo M, García-García L, Cantón R, et al. Clinical and microbiological features of a cystic fibrosis patient chronically colonized with Pandoraea sputorum identified by combining 16S rRNA sequencing and matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2012;50:1096–8. https://doi.org/10.1128/JCM.05730-11.PubMedPubMedCentralCrossRef

41.

Kokcha S, Bittar F, Reynaud-Gaubert M, Mely L, Gomez C, Gaubert JY, et al. Pandoraeapulmonicola chronic colonization in a cystic fibrosis patient, France. New Microbes New Infect. 2013;1:27–9. https://doi.org/10.1002/2052-2975.16.PubMedPubMedCentralCrossRef

42.

Puges M, Debelleix S, Fayon M, Megraud F, Fayon M, Megraud F, et al. Persistent infection because of Pandoraea sputorum in a young cystic fibrosis patient resistant to antimicrobial treatment. Pediatr Infect Dis J. 2015;34(10):1135–7. https://doi.org/10.1097/INF.0000000000000843.PubMedCrossRef

43.

Jørgensen IM, Johansen HK, Frederiksen B, Pressler T, Hansen A, Vandamme P, Koch C. Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients. Pediatr Pulmonol. 2003;36(5):439–46.PubMedCrossRef

44.

Costello A, Herbert G, Fabunmi L, Schaffer K, Kavanagh KA, Caraher EM, et al. Virulence of an emerging respiratory pathogen, genus Pandoraea, in vivo and its interactions with lung epithelial cells. J Med Microbiol. 2011;60:289–99. https://doi.org/10.1099/jmm.0.022657-0.PubMedCrossRef

45.

Speert DP, Henry D, Vandamme P, Corey M, Mahenthiralingam E. Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg Infect Dis. 2002;8(2):181.PubMedPubMedCentralCrossRef

46.

Caraher E, Collins J, Herbert G, Murphy PG, Gallagher CG, Crowe MJ, McClean S. Evaluation of in vitro virulence characteristics of the genus Pandoraea in lung epithelial cells. J Med Microbiol. 2008;57(1):15–20.PubMedCrossRef

47.

Davies D, Parsek M, Pearson J, Iglewski B, Costerton J, Greenberg E. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science. 1998;280:295–8.PubMedCrossRef

48.

Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318e1322.PubMedCrossRef

Title: Isolation and identification of Pandoraea spp. From bronchoalveolar lavage of cystic fibrosis patients in Iran
Authors: Mohammad Tabatabaei
Mahdi Dastbarsar
Mohammad Ashkan Moslehi
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Imipenem
Expectoration
Cystic Fibrosis
Gentamicin
Amikacin
Antibiotic
Piperacillin
Cystic Fibrosis
Polymerase Chain Reaction
Published in: Italian Journal of Pediatrics / Issue 1/2019
Electronic ISSN: 1824-7288
DOI: https://doi.org/10.1186/s13052-019-0687-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Isolation and identification of Pandoraea spp. From bronchoalveolar lavage of cystic fibrosis patients in Iran

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Italian guidelines for the prevention and management of dental trauma in children

Why is “early childhood intensive care” an Italian association of neonatology study group?

Predictors of mortality among HIV exposed infants at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia

Knowledge, attitude and disinformation regarding vaccination and immunization practices among healthcare workers of a third-level paediatric hospital

A solution based on melatonin, tryptophan, and vitamin B6 (Melamil Tripto©) for sedation in newborns during brain MRI

Adolescent selfie: an Italian Society of Paediatrics survey of the lifestyle of teenagers